Immune‐related Adverse Events in Cancer Patients
Open Access
- 5 May 2018
- journal article
- research article
- Published by Wiley in Academic Emergency Medicine
- Vol. 25 (7), 819-827
- https://doi.org/10.1111/acem.13443
Abstract
The U.S. Food and Drug Administration has approved immune checkpoint inhibitors and chimeric antigen receptor T cells (CAR‐T cells) as immunotherapy strategies for cancer. These therapies cause a wide variety of adverse events, which mimic other disease states and may emerge months after completion of treatment. This is important because ascertaining a past medical history of cancer treatment within the past year becomes necessary for many presentations. This narrative review summarizes the biology, pathophysiology, and adverse events associated with checkpoint inhibitors and CAR‐T cells and provides a rational approach to management. Proper treatment begins with heightened awareness, rapid diagnosis, and discussion with the patient's oncologist. Treatment of these adverse effects requires only corticosteroids, infliximab, tocilizumab, or fluids or vasopressors when clinically indicated.Keywords
Funding Information
- National Institutes of Health (P30 CA008748)
This publication has 32 references indexed in Scilit:
- Trends in Adult Cancer–Related Emergency Department UtilizationJAMA Oncology, 2017
- PD1 signal transduction pathways in T cellsOncotarget, 2017
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsCancer Immunology Research, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyFrontiers in Pharmacology, 2017
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 AgentsThe Oncologist, 2016
- Anticipating the “Silver Tsunami”: Prevalence Trajectories and Co-Morbidity Burden among Older Cancer Survivors in the United StatesCancer Epidemiology, Biomarkers & Prevention, 2016
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic MelanomaClinical Cancer Research, 2011
- CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentSeminars in Radiation Oncology, 2003